This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma.
The primary objective is the pathological complete response(pCR)rate following neoadjuvant therapy. The secondary objective includes the major pathological response(MPR)rate following neoadjuvant therapy, the objective response rate (ORR), Organ preservation rate, Surgery postponement rate, event-free survival (EFS), overall survival(OS), and safety.
Aged ≥ 18, male or female;
Histopathologically confirmed Hypopharyngeal Squamous Cell Carcinoma;
Surgically resectable, Clinical Stage III or IV and no distant metastasis (AJCC 8th edition);
Patients with distant metastasis;
Patients with uncontrolled severe medical conditions;
Patients with a history of allergy or hypersensitivity to any component of monoclonal antibody therapies;
Uncontrolled cardiac clinical symptoms or diseases;